Phase
Condition
Ulcerative Colitis
Inflammatory Bowel Disease
Crohn's Disease (Pediatric)
Treatment
vitamin D3
Clinical Study ID
Ages 5-25 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Existing diagnosis of IBD, including Crohn disease, ulcerative colitis, andindeterminate colitis
Receiving treatment with Infliximab or Vedolizumab every 4-8 weeks
Age 5-25 years old, at study entry
Measured serum level of 25-OHD of less than 40 ng/mL in the last 4-8 weeks and nochanges in vitamin D supplementation in the interim. Of note, 25-OHD levels areevaluated routinely as part of standard clinical care for IBD
Exclusion
Exclusion Criteria:
History of any underlying kidney disease
History of preexisting liver disease
History of granulomatous disease
Inability to take oral vitamin D3 as a pill
History of hypercalcemia or hypercalciuria
Currently, or within the past 3 months, taking an anti-epileptic medication or Lasix
Study Design
Study Description
Connect with a study center
Boston Children's Hospital
Boston, Massachusetts 02115
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.